Title: Identification of apoptosis and macrophage migration events in paraquat-induced oxidative stress using a zebrafish model.
Journal: Life sciences20160715
Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Journal: The Biochemical journal20130415
Title: The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS.
Journal: British journal of pharmacology20130301
Title: Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
Journal: Journal of medicinal chemistry20121227
Title: Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
Journal: British journal of cancer20120925
Title: [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Journal: Magyar onkologia20120901
Title: Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.
Journal: Cancer metastasis reviews20120601
Title: Gastrointestinal stromal tumors.
Journal: International journal of colorectal disease20120601
Title: Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
Journal: Lung cancer (Amsterdam, Netherlands)20120601
Title: Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats.
Journal: Neurochemistry international20120501
Title: Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20120501
Title: HPLC-DAD protein kinase inhibitor analysis in human serum.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20120415
Title: Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives.
Journal: Archiv der Pharmazie20120401
Title: The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?
Journal: Arzneimittel-Forschung20120401
Title: Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology20120301
Title: [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Journal: Magyar onkologia20120301
Title: Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.
Journal: Journal of veterinary pharmacology and therapeutics20120201
Title: Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.
Journal: Journal of oncology20120101
Title: Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.
Journal: Journal of oncology20120101
Title: Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.
Journal: Journal of oncology20120101
Title: Ovarian cancer: opportunity for targeted therapy.
Journal: Journal of oncology20120101
Title: Aflibercept in the treatment of metastatic colorectal cancer.
Journal: Clinical Medicine Insights. Oncology20120101
Title: The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Journal: International journal of molecular sciences20120101
Title: Diabetic macular edema: current and emerging therapies.
Journal: Middle East African journal of ophthalmology20120101
Title: The past, present, and future of exudative age-related macular degeneration treatment.
Journal: Middle East African journal of ophthalmology20120101
Title: Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Journal: PloS one20120101
Title: Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.
Journal: PloS one20120101
Title: Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Journal: PloS one20120101
Title: Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Journal: Current cancer drug targets20111101
Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Journal: Nature biotechnology20111101
Title: A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Journal: Clinical advances in hematology & oncology : H&O20111101
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology20111030
Title: Medical treatment of recurrent meningiomas.
Journal: Expert review of neurotherapeutics20111001
Title: HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.
Journal: PLoS genetics20111001
Title: Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Journal: Leukemia research20110901
Title: A computational approach to finding novel targets for existing drugs.
Journal: PLoS computational biology20110901
Title: Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Journal: World journal of gastroenterology20110821
Title: Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110715
Title: Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Journal: International journal of oncology20110701
Title: Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Journal: Journal of neuro-oncology20110601
Title: Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Journal: European journal of medicinal chemistry20110601
Title: Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Journal: British journal of cancer20110524
Title: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20110520
Title: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20110520
Title: Vatalanib in advanced colorectal cancer: two studies with identical results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20110520
Title: A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
Journal: Cancer investigation20110501
Title: Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Journal: Current oncology reports20110401
Title: The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRβ pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis.
Journal: The American journal of pathology20110401
Title: Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.
Journal: North American journal of medical sciences20110401
Title: Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Journal: Annals of surgical oncology20110201
Title: Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
Journal: Cancer chemotherapy and pharmacology20110101
Title: Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.
Journal: mAbs20110101
Title: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches.
Journal: Radiation oncology (London, England)20110101
Title: Novel therapeutic strategies for targeting liver cancer stem cells.
Journal: International journal of biological sciences20110101
Title: In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
Journal: PloS one20110101
Title: Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration.
Journal: Indian journal of ophthalmology20110101
Title: Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.
Journal: Radiation oncology (London, England)20110101
Title: Age-related macular degeneration.
Journal: Clinical ophthalmology (Auckland, N.Z.)20110101
Title: Biomarkers in tumor angiogenesis and anti-angiogenic therapy.
Journal: International journal of molecular sciences20110101
Title: Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels.
Journal: Clinical proteomics20110101
Title: Cell death signaling and anticancer therapy.
Journal: Frontiers in oncology20110101
Title: Investigational approaches for mesothelioma.
Journal: Frontiers in oncology20110101
Title: Pyridylmethylthio derivatives as VEGF inhibitors. Part 1.
Journal: Bioorganic & medicinal chemistry letters20101215
Title: The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.
Journal: Toxicology and applied pharmacology20101201
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology20101124
Title: Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
Journal: Cancer20101101
Title: Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V20101101
Title: Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Journal: European journal of medicinal chemistry20101101
Title: A phase 2 study of vatalanib in metastatic melanoma patients.
Journal: European journal of cancer (Oxford, England : 1990)20101001
Title: PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
Journal: Genes & development20101001
Title: A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Journal: British journal of cancer20100928
Title: Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20100815
Title: A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology20100801
Title: Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant.
Journal: Leukemia & lymphoma20100801
Title: Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives.
Journal: European journal of medicinal chemistry20100801
Title: Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia.
Journal: Journal of vascular surgery20100801
Title: VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane.
Journal: Microcirculation (New York, N.Y. : 1994)20100801
Title: Everolimus in renal cell carcinoma.
Journal: Drugs of today (Barcelona, Spain : 1998)20100801
Title: The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20100701
Title: Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.
Journal: British journal of cancer20100629
Title: Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy20100601
Title: Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Journal: Cancer biology & therapy20100601
Title: Why not treat human cancer with interleukin-1 blockade?
Journal: Cancer metastasis reviews20100601
Title: [Effects of PTK787 on cell proliferation and expression of fak mRNA in K562].
Journal: Zhongguo shi yan xue ye xue za zhi20100601
Title: Targeted therapies in renal cell cancer: recent developments in imaging.
Journal: Targeted oncology20100601
Title: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
Journal: Anticancer research20100601
Title: Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
Journal: The oncologist20100501
Title: Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Journal: Angiogenesis20100301
Title: Molecular therapy of pancreatic cancer.
Journal: Minerva endocrinologica20100301
Title: Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
Journal: Neoplasia (New York, N.Y.)20100201
Title: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
Journal: British journal of cancer20100105
Title: EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Journal: European journal of cancer (Oxford, England : 1990)20100101
Title: Antivascular therapy for epithelial ovarian cancer.
Journal: Journal of oncology20100101
Title: Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
Journal: PloS one20100101
Title: Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.
Journal: PPAR research20100101
Title: Progress on antiangiogenic therapy for patients with malignant glioma.
Journal: Journal of oncology20100101
Title: Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.
Journal: Journal of oncology20100101
Title: Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Journal: Swiss medical weekly20100101
Title: Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.
Journal: Journal of oncology20100101
Title: Clinical trials with anti-angiogenic agents in hematological malignancies.
Journal: Journal of angiogenesis research20100101
Title: Advances in cellular therapy for the treatment of thyroid cancer.
Journal: Journal of oncology20100101
Title: Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.
Journal: Mediators of inflammation20100101
Title: Present and future evolution of advanced breast cancer therapy.
Journal: Breast cancer research : BCR20100101
Title: Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.
Journal: Case reports in oncology20100101
Title: Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Journal: Clinical and experimental gastroenterology20100101
Title: Chemical constituents from Clematis delavayi var. spinescens.
Journal: Molecules (Basel, Switzerland)20091105
Title: A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20091101
Title: Drug release from MCC- and carrageenan-based pellets: experiment and theory.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V20091001
Title: Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers.
Journal: International journal of pharmaceutics20091001
Title: Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258.
Journal: Laboratory investigation; a journal of technical methods and pathology20091001
Title: Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.
Journal: Neoplasia (New York, N.Y.)20090901
Title: Anti-angiogenic therapies for metastatic colorectal cancer.
Journal: The Cochrane database of systematic reviews20090708
Title: PTK787/ZK 222584 inhibits tumor growth promoting mesenchymal stem cells: kinase activity profiling as powerful tool in functional studies.
Journal: Cancer biology & therapy20090701
Title: The selective VEGFR inhibitor PTK787/ZK 222584 represses the activities of VEGFR-negative bone marrow-derived mesenchymal stem cells.
Journal: Cancer biology & therapy20090701
Title: Treatment in advanced colorectal cancer: what, when and how?
Journal: British journal of cancer20090602
Title: The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.
Journal: Cancer research20090601
Title: Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Journal: Experimental hematology20090601
Title: Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Journal: Cancer20090515
Title: VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
Journal: Expert opinion on investigational drugs20090501
Title: Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Journal: The oncologist20090501
Title: Structural adaptation and heterogeneity of normal and tumor microvascular networks.
Journal: PLoS computational biology20090501
Title: Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis.
Journal: American journal of physiology. Heart and circulatory physiology20090301
Title: (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2.
Journal: Bioorganic & medicinal chemistry letters20090301
Title: mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20090301
Title: Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory.
Journal: Brain research20090223
Title: 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.
Journal: Bioorganic & medicinal chemistry letters20090215
Title: A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.
Journal: Investigational new drugs20090201
Title: PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.
Journal: Laboratory investigation; a journal of technical methods and pathology20090201
Title: Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Journal: Molecular cancer therapeutics20090101
Title: Tyrosine kinase blockers: new hope for successful cancer therapy.
Journal: Anti-cancer agents in medicinal chemistry20090101
Title: Emerging pharmacologic therapies for wet age-related macular degeneration.
Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde20090101
Title: Age-related macular degeneration: experimental and emerging treatments.
Journal: Clinical ophthalmology (Auckland, N.Z.)20090101
Title: Current available therapies and future directions in the treatment of malignant gliomas.
Journal: Biologics : targets & therapy20090101
Title: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.
Journal: Journal of angiogenesis research20090101
Title: Effect of PTK/ZK on the angiogenic switch in head and neck tumors.
Journal: Journal of dental research20081201
Title: Exploring multi-targeting strategies for the treatment of gliomas.
Journal: Current opinion in investigational drugs (London, England : 2000)20081201
Title: Small molecule tyrosine kinase inhibitors in pancreatic cancer.
Journal: Biologics : targets & therapy20081201
Title: Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.
Journal: The American journal of pathology20081001
Title: Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.
Journal: Current pharmaceutical design20081001
Title: Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20080901
Title: Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines.
Journal: Molecules (Basel, Switzerland)20080624
Title: Systemic treatments for mesothelioma: standard and novel.
Journal: Current treatment options in oncology20080601
Title: Current and emerging therapies for the treatment of age-related macular degeneration.
Journal: Clinical ophthalmology (Auckland, N.Z.)20080601
Title: Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity.
Journal: Bioorganic & medicinal chemistry letters20080501
Title: Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Journal: Investigative ophthalmology & visual science20080501
Title: [Antiangiogenic agents and gastrointestinal cancers].
Journal: Gastroenterologie clinique et biologique20080501
Title: A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.
Journal: PLoS medicine20080501
Title: Vascular endothelial growth factor in chronic rat allograft nephropathy.
Journal: Transplant immunology20080501
Title: [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Journal: Zentralblatt fur Chirurgie20080401
Title: A conserved role of the VEGF pathway in angiogenesis of an ectodermally-derived vasculature.
Journal: Developmental biology20080301
Title: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology20080101
Title: Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
Journal: Anti-cancer drugs20080101
Title: A quantitative analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology20080101
Title: [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Journal: Bulletin du cancer20080101
Title: Neovascular age-related macular degeneration: potential therapies.
Journal: Drugs20080101
Title: Vascular involvement in rheumatic diseases: 'vascular rheumatology'.
Journal: Arthritis research & therapy20080101
Title: Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis.
Journal: Genome informatics. International Conference on Genome Informatics20080101
Title: A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.
Journal: Clinical medicine. Oncology20080101
Title: A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Journal: Proceedings of the National Academy of Sciences of the United States of America20071218
Title: Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Journal: International journal of cancer20071215
Title: Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Journal: Current opinion in investigational drugs (London, England : 2000)20071201
Title: New approaches in angiogenic targeting for colorectal cancer.
Journal: World journal of gastroenterology20071128
Title: Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
Journal: Clinical colorectal cancer20071101
Title: Chemoradiotherapy in malignant glioma: standard of care and future directions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20070910
Title: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.
Journal: Biochimica et biophysica acta20070901
Title: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.
Journal: Bioorganic & medicinal chemistry letters20070701
Title: PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Journal: Leukemia research20070701
Title: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
Journal: The Journal of dermatology20070701
Title: Lessons learned in the development of targeted therapy for malignant gliomas.
Journal: Molecular cancer therapeutics20070701
Title: [Oral drugs inhibiting the VEGF pathway].
Journal: Bulletin du cancer20070701
Title: [Anti-angiogenic treatment and colorectal cancer].
Journal: Bulletin du cancer20070701
Title: Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Journal: Bioorganic & medicinal chemistry20070601
Title: 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Journal: Journal of medicinal chemistry20070503
Title: 1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.
Journal: Chemical biology & drug design20070501
Title: Novel agents and targets for the therapy of advanced colon cancer.
Journal: Clinical advances in hematology & oncology : H&O20070501
Title: Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Journal: Reviews on recent clinical trials20070501
Title: A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology20070401
Title: Biological therapy update in colorectal cancer.
Journal: Expert opinion on biological therapy20070401
Title: Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Journal: The oncologist20070401
Title: ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
Journal: Bioorganic & medicinal chemistry letters20070301
Title: Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
Journal: Expert opinion on investigational drugs20070301
Title: Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis.
Journal: Clinical colorectal cancer20070301
Title: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Journal: Annals of surgical oncology20070201
Title: Targeted therapy of breast cancer.
Journal: Current pharmaceutical design20070101
Title: Rationale and clinical results of multi-target treatments in oncology.
Journal: The International journal of biological markers20070101
Title: Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy20070101
Title: Metastatic colorectal cancer: current systemic treatment options.
Journal: Drugs20070101
Title: Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.
Journal: Breast cancer research : BCR20070101
Title: Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen.
Journal: Gene regulation and systems biology20070101
Title: Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration.
Journal: Core evidence20070101
Title: 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
Journal: Chemical biology & drug design20061201
Title: Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies.
Journal: Oncology (Williston Park, N.Y.)20061201
Title: Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules.
Journal: Journal of controlled release : official journal of the Controlled Release Society20061128
Title: Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.
Journal: American journal of respiratory and critical care medicine20061115
Title: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Journal: Drug metabolism and disposition: the biological fate of chemicals20061101
Title: Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.
Journal: ChemMedChem20061101
Title: 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
Journal: Chemical biology & drug design20061101
Title: Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Journal: AJR. American journal of roentgenology20061001
Title: New molecular targeted therapies in thyroid cancer.
Journal: Anti-cancer drugs20060901
Title: High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.
Journal: Molecular cancer therapeutics20060901
Title: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Journal: Nature medicine20060801
Title: Biological agents versus chemotherapy in the treatment of colorectal cancer.
Journal: Expert opinion on pharmacotherapy20060701
Title: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Journal: Cancer chemotherapy and pharmacology20060601
Title: Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Journal: Leukemia20060601
Title: Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20060601
Title: Clinical implications of angiogenesis in cancers.
Journal: Vascular health and risk management20060601
Title: A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.
Journal: British journal of cancer20060522
Title: Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
Journal: Head & neck20060501
Title: Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
Journal: Bioorganic & medicinal chemistry letters20060401
Title: [Molecular targets in colon cancer].
Journal: Therapeutische Umschau. Revue therapeutique20060401
Title: 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Journal: Bioorganic & medicinal chemistry letters20060315
Title: Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
Journal: Bioorganic & medicinal chemistry letters20060301
Title: N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
Journal: Bioorganic & medicinal chemistry letters20060201
Title: Vascular endothelial growth factor receptor signaling is required for cardiac valve formation in zebrafish.
Journal: Developmental dynamics : an official publication of the American Association of Anatomists20060101
Title: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
Journal: Cancer research20060101
Title: Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
Journal: Nature clinical practice. Oncology20060101
Title: [Some new findings in the pathogenesis of myeloproliferative disorders and new insight into more effective treatment].
Journal: Casopis lekaru ceskych20060101
Title: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.
Journal: The oncologist20060101
Title: Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Journal: Reviews on recent clinical trials20060101
Title: 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Journal: Journal of medicinal chemistry20051201
Title: Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Journal: IDrugs : the investigational drugs journal20051201
Title: Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
Journal: IDrugs : the investigational drugs journal20051201
Title: Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Journal: Cancer research20051201
Title: Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Journal: The Laryngoscope20051201
Title: Update on angiogenesis inhibitors.
Journal: Current opinion in oncology20051101
Title: Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
Journal: IDrugs : the investigational drugs journal20051001
Title: Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Journal: Clinical lung cancer20050901
Title: Targeting multiple signal transduction pathways in lung cancer.
Journal: Clinical lung cancer20050901
Title: Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.
Journal: Journal of medicinal chemistry20050825
Title: PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Journal: NMR in biomedicine20050801
Title: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20050620
Title: Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Journal: Cancer research20050615
Title: The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20050615
Title: Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie20050601
Title: The realisation of targeted antitumour therapy.
Journal: British journal of cancer20050601
Title: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Journal: European journal of cancer (Oxford, England : 1990)20050601
Title: Angiogenesis and lung cancer: prognostic and therapeutic implications.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20050510
Title: The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Journal: British journal of cancer20050509
Title: Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Journal: Cancer research20050501
Title: Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
Journal: Clinical colorectal cancer20050501
Title: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology20050401
Title: Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Journal: Journal of medicinal chemistry20050310
Title: Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice.
Journal: International journal of radiation oncology, biology, physics20050301
Title: A small molecule-kinase interaction map for clinical kinase inhibitors.
Journal: Nature biotechnology20050301
Title: PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Journal: Chembiochem : a European journal of chemical biology20050301
Title: Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
Journal: Academic radiology20050301
Title: Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.
Journal: IDrugs : the investigational drugs journal20050301
Title: Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Journal: Seminars in oncology20050201
Title: Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation.
Journal: Transplantation20050127
Title: [Problems in the current target therapy of malignancies].
Journal: Voprosy onkologii20050101
Title: The fight against cancer: the next round.
Journal: Drug discovery today20041115
Title: Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.
Journal: Nature medicine20041101
Title: A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology20041001
Title: Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
Journal: Clinical colorectal cancer20041001
Title: Future directions with angiogenesis inhibitors in colorectal cancer.
Journal: Clinical colorectal cancer20041001
Title: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Journal: Cancer research20040915
Title: Protein kinase inhibitors: novel tools in cancer therapy.
Journal: Der Urologe. Ausg. A20040901
Title: Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
Journal: Clinical lung cancer20040901
Title: Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Journal: Lung cancer (Amsterdam, Netherlands)20040801
Title: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
Journal: Neurosurgery20040801
Title: Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.
Journal: Oncogene20040603
Title: An image worth a thousand lives?
Journal: Nature biotechnology20040601
Title: Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]20040401
Title: Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.
Journal: Biochimica et biophysica acta20040311
Title: Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
Journal: Endocrinology20040301
Title: Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
Journal: International journal of radiation oncology, biology, physics20040201
Title: Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Journal: Clinical & experimental metastasis20040101
Title: Antiangiogenic therapy: more promise and, yet again, more questions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20031101
Title: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20031101
Title: [Current screening for molecular target therapy of cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy20031101
Title: Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.
Journal: Clinical colorectal cancer20031101
Title: Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.
Journal: Bioorganic & medicinal chemistry letters20030915
Title: The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies.
Journal: Investigative ophthalmology & visual science20030801
Title: PTK/ZK (Novartis).
Journal: IDrugs : the investigational drugs journal20030801
Title: American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
Journal: IDrugs : the investigational drugs journal20030701
Title: Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Journal: Seminars in oncology20030601
Title: MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
Journal: European journal of nuclear medicine and molecular imaging20030301
Title: p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3.
Journal: Genes & development20030215
Title: Novel therapies for multiple myeloma.
Journal: British journal of haematology20030101
Title: Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor.
Journal: Arteriosclerosis, thrombosis, and vascular biology20030101
Title: American Society of Hematology--44th Annual Meeting and Exposition. Drug highlights I. 6-10 December 2002, Philadelphia, PA, USA.
Journal: IDrugs : the investigational drugs journal20030101
Title: Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation.
Journal: Anticancer research20030101
Title: Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Journal: Journal of medicinal chemistry20021219
Title: Inhibitors of the vascular endothelial growth factor receptor.
Journal: Hematology/oncology clinics of North America20021001
Title: New drugs in acute myeloid leukemia.
Journal: Current oncology reports20020901
Title: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Journal: Cancer research20020901
Title: MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model.
Journal: Academic radiology20020801
Title: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Journal: Cancer research20020715
Title: Quantitative and qualitative in vivo angiogenesis assay.
Journal: International journal of oncology20020701
Title: Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis.
Journal: Circulation20020528
Title: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Journal: Cancer research20020401
Title: Dissection of angiogenic signaling in zebrafish using a chemical genetic approach.
Journal: Cancer cell20020401
Title: Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Journal: The Journal of pharmacology and experimental therapeutics20011201
Title: Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Journal: British journal of cancer20011201
Title: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Journal: Cancer biotherapy & radiopharmaceuticals20011001
Title: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Journal: Journal of medicinal chemistry20000615
Title: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Journal: Cancer research20000415
Title: Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8
Title: Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596.
Title: Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308.
